We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 336

An unsuccessful defendant is not entitled to elect an accounting of profits to shield itself from an award of damages
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

On September 7, 2016, the Court held that Bayer's patent was valid and infringed (2016 FC 1013; our summary here). The parties were given an


Appeal relating to double patenting and sufficiency of tadalafil patent dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

The Federal Court of Appeal considered an appeal from Apotex relating to double patenting and insufficiency of a patent claiming the use of tadalafil


Supreme Court Updates
  • Borden Ladner Gervais LLP
  • Canada
  • October 26 2016

The Federal Court has allowed Apotex to amend its statement of defence to include a new anticipation claim and a new defence of issue estoppel and


Patent anticipated by hearsay documents that met the test of necessity due to failure to comply with Federal Courts Rules
  • Borden Ladner Gervais LLP
  • Canada
  • October 26 2016

The Federal Court dismissed Gilead's application for prohibition in respect to the combination drug TUVADA covered in the '475 Patent. This


Cross-licensing agreements held to not trigger the requirement to send a Notice of Allegation under the PM(NOC) Regulations
  • Borden Ladner Gervais LLP
  • Canada
  • October 19 2016

The Federal Court of Appeal has overturned two decisions of the Federal Court, relating to the issuance of an NOC to a generic company who did not


Expert "Blinding" is a Question of Relevance, Reliability and Weight, but not Admissibility
  • Borden Ladner Gervais LLP
  • Canada
  • October 12 2016

On August 23, 2016, the Federal Court released its public judgment granting the Order of prohibition for Gilead's ‘619 Patent. The ‘619 Patent


NOA found to be deficient for failing to plead the facts and law relating to the manufacture and importation of the drug product
  • Borden Ladner Gervais LLP
  • Canada
  • October 5 2016

Bayer has obtained an order of prohibition against the Minister of Health from issuing a NOC to Fresenius for its proposed moxifloxacin hydrochloride


Court of appeal upholds finding of infringement and only requires a "mere scintilla" of utility
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

The Federal Court of Appeal has dismissed Nova's appeal of an earlier finding that it had infringed Dow's patent relating to polyethylene used to make


Trial judge acknowledges stare decisis and comity in relation to findings from the previous NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

This was a patent infringement action against Apotex and Cobalt, relating to a combination of drospirenone and ethinylestradiol for an effective oral


Court of Appeal upholds construction of the promise distinguishing between the compounds and use claims
  • Borden Ladner Gervais LLP
  • Canada
  • September 21 2016

The Federal Court of Appeal dismissed an appeal from a decision prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for